Acadia dumps schizophrenia drug after Phase I miss; Quintiles and Allscripts team up on clinical research software;

 @FierceBiotech: GSK, ‪Theravance‬ hit up regulators for approval of key asthma/COPD drug. More | Follow @FierceBiotech

 @JohnCFierce: AstraZeneca's Link deal all about getting its new iMed - small, semi-virtual discovery unit - in gear. Wheelin/dealin. Item | Follow @JohnCFierce

 @RyanMFierce: BB Biotech rejected unsolicited proposal to take co private, says shares bested the Swiss mkt. Is that enough? Release | Follow @RyanMFierce

> Acadia Pharmaceuticals ($ACAD) has scrapped development of a schizophrenia drug, AM-831, after the candidate missed the main goal of an early-stage study. Article

> Pharma services giant Quintiles has teamed up with healthcare tech provider Allscripts to develop clinical research software. Report

> Affymax's ($AFFY) shares jumped after the biotech and Takeda struck a supply agreement for their anemia drug Omontys with Fresenius. Item

> OncoMed Pharmaceuticals has kicked off a Phase I clinical trial for OMP-54F28 in patients with advanced solid tumors. The drug, which is designed to attack cancer stem cells, is being developed in partnership with Bayer Healthcare. News

Pharma News

 @FiercePharma: Emerging-markets demand saves French plant where ‪Ipsen‬ makes primary care meds. News  | Follow @FiercePharma

> Forest independents immediately tell Carl Icahn no. News

> India to destroy 27M doses of BCG vaccine as shortages loom elsewhere. More

> China may not produce for Big Pharma long-term. Article

> 2,500 Sanofi jobs may be marched off patent cliff. Story

Medical Device News

@FierceMedDev: While purchasers praise the FDA's device ID plan, members of the industry remain wary. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Devicemaker B. Braun is moving to block Fresenius' purchase of Germany's Rhoen. More | Follow @DamianFierce

> IntegraGen snags $2.4M to market autism Dx. More

> LabCorp's $241M Medtox buyout plan clears hurdle. Article

> FDA unveils draft guidance for quick feedback on devices. News

> Higher user fees may not speed up device regulatory approvals. Story

And Finally…  Three drinks a week could keep arthritis away, according to a new study. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.